Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 [TA878], NICE (updated 5th April 2023)
Increased risk for progression to severe COVID added as new recommendation for use for nirmatrelvir plus ritonavir and sotrovimab as per independent advisory group report commissioned by the Department of Health and Social Care.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
More News: Actemra | COVID-19 | Department of Health | Health | National Institute for Health and Clinical Excelle | Norvir